Page last updated: 2024-12-11

e 5531

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

E 5531: endotoxin antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6442269
SCHEMBL ID610334
MeSH IDM0245018

Synonyms (10)

Synonym
e 5531
e-5531
162679-36-9
unii-4468vt5e70
e5531
4468vt5e70 ,
[(3r)-1-[(2r,3r,4r,5s,6r)-2-[[(2r,3s,4r,5r,6r)-3-hydroxy-4-[(3r)-3-hydroxydecoxy]-5-(3-oxotetradecanoylamino)-6-phosphonooxyoxan-2-yl]methoxy]-6-(methoxymethyl)-3-(3-oxotetradecanoylamino)-5-phosphonooxyoxan-4-yl]oxydecan-3-yl] (z)-dodec-5-enoate
SCHEMBL610334
.alpha.-d-glucopyranose, 2-deoxy-6-o-(2-deoxy-2-((1,3-dioxotetradecyl)amino)-6-o-methyl-3-o-((3r)-3-(((5z)-1-oxo-5-dodecen-1-yl)oxy)decyl)-4-o-phosphono-.beta.-d-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-3-o-((3r)-3-hydroxydecyl)-, 1-(dihydrogen phos
DB06447

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" All doses of E5564 were demonstrated to be safe and well tolerated."( Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
Carter, A; Kao, R; Lynn, M; Rose, JR; Rossignol, D; Wong, YN, 2003
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
") infusion, (2) evaluate the pharmacokinetic profile of E5564, and (3) measure the ability of E5564 to block LPS stimulation ex vivo in blood taken from subjects up to 8 hours after ending the infusion."( Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
Carter, A; Kao, R; Lynn, M; Rose, JR; Rossignol, D; Wong, YN, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (41.38)18.2507
2000's16 (55.17)29.6817
2010's1 (3.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.62 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.34%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]